Megalencephalic leukoencephalopathy with subcortical cysts 1 (MLC1)

Megalencephalic leukoencephalopathy with subcortical cysts 1 (MLC1) is an integral membrane protein predominantly expressed in the central nervous system, specifically within astrocytes at the perivascular end-feet and perisynaptic processes (UniProt Q15049, NIH.gov). It functions as a key regulator of brain ion and water homeostasis, primarily by modulating the activity of volume-regulated anion channels (VRAC) and other transporters like ClC-2 and TRPV4 (GeneCards, PubMed 22328087). Loss-of-function mutations in the MLC1 gene are the primary cause of Megalencephalic Leukoencephalopathy with subcortical Cysts (MLC), a rare and progressive leukodystrophy (NIH GeneReviews). This condition is characterized by early-onset macrocephaly, subcortical cysts, and chronic white matter edema due to impaired astrocyte volume regulation (Neurology.org). Beyond its role in osmoregulation, MLC1 interacts with GlialCAM and the V-ATPase complex to influence endosomal pH and protein recycling (PubMed 31209783). While there are currently no approved pharmacological treatments targeting MLC1, experimental approaches such as gene therapy and pharmacological chaperones are being investigated to restore its function (AllianceMLC.org, eLife 2021). The protein's involvement in astrocyte reactivity also suggests its potential relevance in broader neuroinflammatory and neurodegenerative diseases like Multiple Sclerosis and Alzheimer's (PubMed 31209783).

Other names

MLC1LVMKIAA0027VLWKL1Megalencephalic leukoencephalopathy with subcortical cysts protein 1Membrane protein MLC1

Restoration of MLC1 protein expression in astrocytes via gene replacement or stabilization of mutant protein folding to restore trafficking and ion channel modulation.